Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis

Jing Zhao MD | Yuanyuan Zeng MD | Xiaoxu Shen MD, Ph.D

Abstract
Some randomized controlled trials have compared the effectiveness and safety outcomes between early initiation of Sacubitril/Valsartan and angiotensin-converting enzyme inhibitors (ACEIs) in patients after acute myocardial infarction. Therefore, our current meta-analysis aimed to clarify the confusion. Four Databases and relevant grey literature were searched for studies from inception to July 2, 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias. Four studies involving 6154 patients were included to perform meta-analysis. The results of meta-analysis showed that the left ventricular ejection fraction in the Sacubitril/Valsartan group was higher than the ACEI group (SMD: 0.37, 95% CI: 0.19–0.55, \( P = .000 \)), the incidence of major adverse cardiac events in the Sacubitril/Valsartan group was lower than the ACEI group (RR: 0.61, 95% CI: 0.46–0.82, \( P = .001 \)), while the incidences of cardiac death (RR: 1.00, 95% CI: 0.81–1.24, \( P = 1.000 \)) and the heart failure hospitalization (RR: 0.62, 95% CI: 0.37–1.03, \( P = .065 \)) showed no difference. For the incidences of myocardial infarction and the adverse side effects, there was no obvious advantage of the Sacubitril/Valsartan group over the ACEI group, because the meta-analysis was not performed due to the limited trials. This study indicated that early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction was superior to ACEI in reducing the risks of major adverse cardiac events and left ventricular ejection fraction increasing. As for the other outcomes (the incidences of cardiac death, the heart failure hospitalization, the myocardial infarction and the adverse side effects), Sacubitril/Valsartan showed no obvious advantage than ACEI.

KEYWORDS
acute myocardial infarction, early initiation, meta-analysis, Sacubitril/Valsartan
receptor blockers (ARBs) inhibit the activation of RAAS by blocking the conversion of angiotensin I into angiotensin II and interfering with the binding of angiotensin II to its receptor, respectively. Early initiation of ACEI from MI symptom onset could reduce 30-day mortality and HF by 7% and 4%, respectively.4 ARBs are used in patients with intolerance of ACEIs.5,6

Sacubitril/Valsartan, which consists of the neprilysin inhibitor sacubitril and the ARB valsartan, has been approved for patients with symptomatic heart failure with reduced ejection fraction (HFrEF) and is intended to be substituted for ACEIs or ARBs.7,8 In the PARADIGM-HF study, Sacubitril/Valsartan in HFrEF patients reduced HF hospitalization by 20% compared with ACEI enalapril.7 The PIONEER-HF study showed that early initiation of Sacubitril/Valsartan in MI patients with left ventricular systolic dysfunction could reduce the level of NT-pro BNP.9 In recent years, many researchers focused on whether AMI patients benefit of early initiation of Sacubitril/Valsartan.10–12 However, there is still a lack of relevant clinical evidence. Therefore, we conducted this meta-analysis to investigate the efficacy and safety of early initiation of Sacubitril/Valsartan in patients after AMI.

2 | METHODS

Our current meta-analysis was performed based on the Cochrane handbook for systematic reviews. The results of this study were arranged based on the Preferred Reporting Items for Reporting Systematic Reviews and Meta-analyses (PRISMA). The data, methods, and materials of this study are available to others for purposes of reproducing the results or replicating procedures by contacting the corresponding author.

2.1 | Search strategy

Databases including Web of Science, PubMed, Embase, and the Cochrane Library were searched for relevant studies from inception to July 2, 2021. The relevant grey literature, like reports and conference abstracts on the Internet, was also searched. The search terms were as follows: myocardial infarction, sacubitril-valsartan, sacubitril valsartan sodium hydrate, LCZ 696, angiotensin receptor neprilysin inhibitor, and randomized controlled trial. All searches were performed independently by two reviewers. Discrepancies between reviewers were resolved by discussion or by a third reviewer.

2.2 | Study eligibility

Eligible studies must meet the following criteria: (a) randomized controlled trial (RCT) focused on the patients after AMI occurred within 1 month as well as hemodynamics permit, (b) the comparisons of outcomes between Sacubitril/Valsartan and ACEIs, (c) the effectiveness outcomes included cardiac death, MI, HF hospitalization, major adverse cardiac events (MACE) and left ventricular ejection fraction (LVEF), the safety outcomes including adverse side effects.

The exclusion criteria were as follows: (a) studies were duplicated publications, (b) studies without useable data, (c) pediatric, animal or cell studies, (d) studies were published in non-English or non-Chinese.

2.3 | Data extraction

Two investigators extracted the following data independently from each of the studies included: the first author, year of publication, study country, funding support, patient characteristics (age, sex ratio), interventions (grouping, sample size, types of drugs, intervention duration), outcomes. In the case of missing information in the included studies, investigators were contacted by email to obtain the missing information.

2.4 | Quality assessment

Two independent reviewers assessed the risk of bias of all included trials and completed a Risk of Bias Table as described in chapter 8 of the Cochrane Handbook.13

2.5 | Statistical analysis

The meta-analysis was conducted by Stata 15.0 software. Heterogeneity between trial results was tested using the Q test and the $I^2$ statistic where percentages greater than 50% were taken to indicate significant heterogeneity. If heterogeneity was detected for outcomes, meta regression, subgroup analysis and sensitivity analysis were performed to analyze the causes of heterogeneity. The test level of meta regression was set as $\alpha = 0.1$. Funnel plot was used to evaluate the publication bias. The test level of meta-analysis was set as $\alpha = 0.05$.

3 | RESULTS

3.1 | Search results and population characteristics

The study selection process was illustrated in Figure 1. We identified 66 records in the initial search. After removing duplicates and screening, four studies were eligible for inclusion in our meta-analysis. The population characteristics of the patients were summarized in Table 1.

3.2 | Quality assessment

The Cochrane Collaboration’s tool for assessing risk of bias was used to assessing the bias of studies included (Table 2). Rezq14 declared that the random numbers were computer-generated. Kunbhani17 declared that the patients were randomized via an interactive
response technology. Only Wang\textsuperscript{15} noted that the patients were assigned by the envelope method.

### 3.3 Cardiac death outcome in patients after AMI

Three trials\textsuperscript{14,15,17} involving 5998 patients reported cardiac death outcome. The significant heterogeneity was not noted between the included studies ($I^2 = 24.7\%$, $P = .265$). Therefore, the fixed-effects M-H model was used. The meta-analysis showed that no significant difference in the incidence of cardiac death was noted between the Sacubitril/Valsartan group and the ACEI group (RR: 1.00, 95% CI: 0.81–1.24, $P = 1.000$; Figure 2(A)).

### 3.4 MI outcome in patients after AMI

Two trials\textsuperscript{14,15} involving 337 patients reported myocardial infarction outcome. However, a meta-analysis could not be performed due to the limited number of trials. Rezq’s study\textsuperscript{14} showed that the incidence of MI in the Sacubitril/Valsartan group was lower than that in the ACEI group (1% vs. 2%). On the contrary, Wang’s study\textsuperscript{15} showed...
3.5  HF hospitalization outcome in patients after AMI

Three trials involving 6017 patients reported HF hospitalization outcome. The significant heterogeneity was noted between the included studies ($I^2 = 69.0\%$, $P = .040$). However, the meta-regression, subgroup analysis or sensitivity analysis could not be performed to analyze the causes of heterogeneity due to the limited number of trials. Therefore, the random-effects I-V model was used. The meta-analysis showed no differences in the incidence of HF hospitalization between the Sacubitril/Valsartan group and the ACEI group (RR: 0.62, 95% CI: 0.37–1.03, $P = .065$; Figure 2(B)).

3.6  MACE outcome in patients after AMI

Three studies involving 493 patients reported the MACE outcome. The significant heterogeneity was not noted between the included studies ($I^2 = 0.0\%$, $P = .414$). Therefore, the fixed-effects M-H model was used. The meta-analysis showed that the incidence of MACE in the Sacubitril/Valsartan group was lower than the ACEI group (RR: 0.61, 95% CI: 0.46–0.82, $P = .001$; Figure 2(C)).
3.7 | LVEF outcome in patients after AMI

Three studies\(^{14-16}\) involving 483 patients reported the LVEF outcome. The significant heterogeneity was not noted between the included studies ($I^2 = 0.0\%$, $P = .399$). Therefore, the fixed-effects M-H model was used. The meta-analysis showed that the LVEF in the Sacubitril/Valsartan group was higher than the ACEI group (SMD: 0.37, 95% CI: 0.19–0.55, $P = .000$; Figure 2(D)).

3.8 | Adverse side effects

Three trials\(^{14,15,17}\) reported adverse side effects. Rezq's study\(^{14}\) showed that no safety adverse events (such as symptomatic hypotension, worsening renal function, or angioedema) were observed between two groups. Thus, a meta-analysis could not be performed due to the limited number of trials. Wang's study\(^{15}\) and Kunbhan's study\(^{17}\) suggested that the incidences of adverse side effects in terms of cough and hyperkalemia were lower in the Sacubitril/Valsartan group than the ACEI group, while the incidence of hypotension in the Sacubitril/Valsartan group was higher than the ACEI group.

4 | DISCUSSION

Since the advent of Sacubitril/Valsartan, its benefits for the HFrEF patients and the HF with preserved ejection fraction patients have been confirmed in PARADIGM-HF study and PARALLAX study, respectively.\(^{18,19}\) The activation of RAAS is the main determinant of the pathophysiology of AMI and HF. Considering that Sacubitril/Valsartan could inhibit the activation of RAAS, many researchers hypothesized that Sacubitril/Valsartan have benefits in patients after AMI.\(^{20,21}\) For these patients, there were still confusions about the benefits and risks of Sacubitril/Valsartan and ACEI. After a comprehensive search and strict screening, a total of four studies involving 6154 patients were included. The quantity of included studies was limited, the reason might be that the relevant trials are ongoing or the results have not yet been published. PARADISE-MI, a multinational, double-blind, active-controlled trial, randomized patients within 0.5–7 days of presentation with index AMI to Sacubitril/Valsartan or ramipril. The design and baseline characteristics of the PARADISE-MI trial have been published.\(^{21}\) The primary results of the PARADISE-MI trial were presented at the American College of Cardiology's 70th Annual Scientific Session,\(^{17}\) but they have not been formally published in sources such as books or journals. After discussion, the PARADISE-MI trial has been considered eligible to be included in this study. The results of meta-analysis showed that the LVEF in the Sacubitril/Valsartan group was higher than the ACEI group, the incidence of MACE in the Sacubitril/Valsartan group was lower than the ACEI group, while the incidences of cardiac death and the HF hospitalization showed no difference.

Owing to limited quantity of trials, the Sacubitril/Valsartan group showed no obvious advantage than the ACEI group in this meta-analysis when comparing the incidences of MI and the adverse side effects. According to the Cochrane Handbook,\(^{22}\) the funnel plot should generally not be considered when the included studies were less than 10, therefore we do not use funnel plot to evaluate the publication bias.

All trials had risks of bias in at least one of several key criteria. Two trials\(^{14,17}\) reported adequate sequence generation and one trial\(^{15}\) reported adequate concealment of allocation. Two trials\(^{15,16}\) had the risk of bias due to absence of blinding of participants and personnel and binding of outcome assessment. The GRADE system entails an assessment of the quality of a body of evidence which involves consideration of within-study risk of bias, directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias for each individual outcome. Although all trials included did not report adequate concealment of allocation, we think that potential limitations were unlikely to lower confidence in the estimate of effect. Since most trials included did not report adequate sequence generation, we think that potential limitations were probably to lower confidence in the estimate of effect. According to that, we downgraded randomized trial evidence of the cardiac death, the HF hospitalization, the MACE and the LVEF outcomes to moderate quality evidence.

4.1 | Limitations

The present analysis has several limitations. Firstly, four RCTs were included in this study, resulting in a small number of included patients. Secondly, most studies included have not reported the sequence generation and allocation concealment which could result in selection bias. Finally, language restriction could have introduced publication bias.

5 | CONCLUSION

This meta-analysis indicated that early initiation of Sacubitril/Valsartan in patients after AMI was superior to ACEI in reducing the risks of MACE and increasing LVEF, while it had no obvious advantage in reducing the risks of cardiac death, HF hospitalization, MI and adverse side effects.

CONFLICT OF INTEREST

All authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

Jing Zhao: data curation, formal analysis, writing-original draft. Yuanyuan Zeng: data curation. Xiaoxu Shen: writing-review and editing.

DATA AVAILABILITY STATEMENT

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited.

ORCID

Jing Zhao \(\text{https://orcid.org/0000-0001-7346-9959}\)
REFERENCES

1. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646-659.
2. Gerber Y, Weston SA, Enriquez-Sarano M, et al. Mortality associated with heart failure after myocardial infarction: a contemporary community perspective. Circ Heart Fail. 2016;9(1):e002460.
3. Wang H, Liang YC. 2018 Chinese guidelines for the diagnosis and treatment of heart failure. Chin J Cardiol. 2018;46(10):760-789.
4. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97(22):2202-2212.
5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
6. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239.
7. McMurray JJ, Packer M, Anker SD, et al. Angiotensin neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(1):993-1004.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.
9. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):1045-1054.
10. ChiCtr. A prospective, randomized, controlled trial for the efficacy and safety of improving left ventricular remodeling in combined use of sacubitril-valsartan and dapagliflozin compared to RAAS inhibitors in very elderly patients with acute myocardial infarction at the early stage of hospitalization. UK: Cochrane Central Register of Controlled Trials; 2020. http://who.int/trialsearch/Trial2asp?TriID=ChiCTR2000035387. Accessed May 13, 2021.
11. EuCtR GB. Studying the effect of medication (sacubitril/valsartan) on heart muscle damage after heart attacks. UK: Cochrane Central Register of Controlled Trials; 2018. http://who.int/trialsearch/Trial2asp?TriID=EuCTR2017-003460-13-GB. Accessed May 13, 2021.
12. Nct. Early Treatment of ARNI on Myocardial Remodeling and Progress. UK: Cochrane Central Register of Controlled Trials; 2018. http://clinicaltrials.gov/show/NCT04342351. Accessed May 13, 2021.
13. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions (version 6.2). London: Cochrane; 2021. http://training.cochrane.org/handbook/current/chapter-08. Accessed May 13, 2021.
14. Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of Sacubitril/Valsartan versus Ramipril in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2021;143:7-13.
15. Wang HY, Fu KH. Effects of sacubitril/valsartan on ventricular remodeling in patients with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coron Artery Dis. 2021;32(5):418-426.
16. Zhang Y, Wu YB, Zhang K, et al. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. 2021;32(5):418-426.
17. Kumbhani DJ. Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction. Washington, DC: The American College of Cardiology; 2021. http://acc.org/latest-in-cardiology/clinical-trials/2021/05/14/01/22/paradisemi. Accessed July 2, 2021.
18. Choi HM, Shin MS. Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence. Korean J Intern Med. 2020;35(3):498-513.
19. Wachter R, Shah SJ, Cowie MR, et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail. 2020;7(3):856-864.
20. Docherty KF, Campbell RT, Brooksbank KJM, et al. The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation. 2021;144(3):199-209. https://doi.org/10.1161/circulationaha.121.054892
21. Jering KS, Clagett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23(6):1040-1048. https://doi.org/10.1002/ejhf.2191
22. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions (version 6.2). London: Cochrane; 2021. http://training.cochrane.org/handbook/current/chapter-13. Accessed May 13, 2021.

How to cite this article: Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis. Clin Cardiol. 2021;44(10):1354-1359. doi:10.1002/clc.23717